Drug lookup | Fillwise

MOXIFLOXACIN HYDROCHLORIDE

All products: not a benefit

Other products in the same Health Canada class (J01MA) — coverage varies; not interchangeable

Ciprofloxacin (Cipro): general benefit, Limited Use 533, Not a benefit
Levofloxacin (Levaquin): general benefit, Not a benefit
Norfloxacin (Noroxin): general benefit, Not a benefit
Ciprofloxacin + ciprofloxacin base (Cipro XL): limited Use 394, Not a benefit

Avelox · DIN 02242965 · 400mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2019-07-04 — choose a marketed DIN from the same-category list.Discontinued 2019-07-04 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2019-07-04 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2019-07-04 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Avelox · DIN 02242965 Manufacturer: Bayer Inc., Consumer Care Division; listing date 2001-06-07 Health Canada: Cancelled post market since 2019-07-04 · brand AVELOX · ATC J01MA14 MOXIFLOXACIN · form Tablet · route Oral · ingredients MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) 400 MG · company Bayer inc · schedule Prescription

Check this DIN again · Health Canada product record

Avelox: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66804 · Verify on the e-Formulary ↗ (DIN 02242965)

Source record

DIN 02242965: Avelox Raw flags: notABenefit=Y, sec3=Y Item: 084000053; group id 137; item number 0230; lccId None; manufacturer id BAY Source form: Tab; strength: 400mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02242965 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66804

Interchangeable products

AG-Moxifloxacin · DIN 02478137 · $1.5230 Apo-Moxifloxacin · DIN 02404923 · $1.5230 Auro-Moxifloxacin · DIN 02432242 · $1.5230 Jamp-Moxifloxacin · DIN 02443929 · $1.5230 Jamp-Moxifloxacin Tablets · DIN 02447061 · $1.5230 M-Moxifloxacin · DIN 02472791 · $1.5230 Mar-Moxifloxacin · DIN 02447053 · $1.5230 Med-Moxifloxacin · DIN 02457814 · $1.5230 Moxifloxacin · DIN 02520710 · $1.5230 Sandoz Moxifloxacin · DIN 02383381 · $1.5230 Teva-Moxifloxacin · DIN 02375702 · $1.5230

Shortage status: discontinued (2019-07-04, reported by BAYER INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242965

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2019-07-04 — choose a marketed DIN from the same-category list.

Other drugs in the same formulary class (08:40 Miscellaneous Anti-Infectives) and how they are covered

Matched class: 08:40 Miscellaneous Anti-Infectives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): CIPROFLOXACIN, LEVOFLOXACIN, NORFLOXACIN, SULFAMETHOXAZOLE & TRIMETHOPRIM, TRIMETHOPRIM 08:40 Miscellaneous Anti-Infectives

CIPROFLOXACIN

· 44 products · Limited Use, codes 533 (1), Listed, not a benefit (3), General benefit (40) · strengths: 10g/100mL, 250mg, 500mg, 750mg · Oral Susp, Tab

LEVOFLOXACIN

· 24 products · Listed, not a benefit (2), General benefit (14), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 250mg, 500mg, 750mg · Tab

NORFLOXACIN

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 400mg · Tab

CIPROFLOXACIN HCL & CIPROFLOXACIN BASE

· 2 products · Listed, not a benefit (1), Limited Use, codes 394 (1) · strengths: 500mg · ER Tab

SULFAMETHOXAZOLE & TRIMETHOPRIM

· 9 products · Listed, not a benefit (6), General benefit (3) · strengths: 40mg & 8mg/mL, 400mg & 80mg, 800mg & 160mg · O/L, Tab

TRIMETHOPRIM

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mg, 200mg · Tab

LINEZOLID

· 6 products · Off-Formulary Interchangeable, not an ODB benefit (2), Listed, not a benefit (1), Limited Use, codes 362, 363, 364 (3) · strengths: 2mg/mL, 600mg · Inj-300mL Pk, Tab

CEFEPIME

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g, 2g · Inj Pd-Vial Pk

ERTAPENEM

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g/Vial · Inj Pd-Vial Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:40

Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:18 Antivirals, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.

Other drugs whose Health Canada label lists a similar indication: patients 1 year of age and older with bacterial conjunctivitis

From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. GATIFLOXACIN · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS ZYMAR® (gatifloxacin) is indicated for the treatment of patients 1 year of age and older with bacterial conjunctivitis caused by susceptible strains of the following bacteria: Aerobic Gram-positive bacteria: • Staphylococcus aureus • Staphylococcus epidermidis • Streptococcus pneumoniae Aerobic Gram-negative bacteria: • Haemophilus influenzae To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYMAR and other antibacterial drugs, ZYMAR should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. 1.1 Pediatrics Pediatrics (≥ 1 year and ≤ 12 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of ZYMAR in pediatric patients 1 year of age and older has been established; therefore, Health Canada has authorized an indication for pediatric use. PM: https://pdf.hres.ca/dpd_pm/00067074.PDF; date AUG 30, 2004; DIN 02257270; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26

What the Health Canada label says it is for

INDICATIONS AND CLINICAL USE VIGAMOX® (moxifloxacin ophthalmic solution) is indicated for the treatment of patients 1 year of age and older with bacterial conjunctivitis caused by susceptible strains of the following organisms: Aerobic, Gram-Positive Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Streptococcus pneumoniae Streptococcus viridans group Aerobic, Gram-Negative Acinetobacter species Haemophilus influenza To reduce the development of the drug-resistant bacteria and maintain the effectiveness of VIGAMOX and other antibacterial drugs, VIGAMOX should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. VIGAMOX® Product Monograph Page 3 of 27 Geriatrics (> 65 years of age): No overall differences in safety and effectiveness have been observed … https://pdf.hres.ca/dpd_pm/00042774.PDF PM date: December 1, 2017 Source product: VIGAMOX; DIN 02252260; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Avelox · DIN 02242965 Shortage status: discontinued (2019-07-04, reported by BAYER INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242965

Check this DIN again

Other review policies

For Avelox: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote

Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote

Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026